US FDA Approves Gene Therapy of Bluebird Bio for Rare Neurological Disorder
The US Food and Drug Administration (FDA) of the United States has approved gene therapy of Bluebird Bio for the treatment of a rare neurological disorder. SKYSONA is the first therapy approved by US FDA shown to slow the progression of neurologic dysfunction in boys with active and early Cerebral Adrenoleukodystrophy (CALD). Bluebird Bio said, […]
Continue Reading